Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtcvs.2020.02.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating diclofenac's risks in COVID-19: strategies for mitigating adverse outcomes.
Inflammopharmacology
November 2024
School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
The use of nonsteroidal anti-inflammatory drugs (NSAIDs), particularly diclofenac, during the COVID-19 pandemic has raised concerns due to its potential to worsen disease progression. This commentary evaluates key risks associated with diclofenac and highlights the critical role of pharmacists in mitigating adverse outcomes through careful medication management and patient education. Diclofenac poses unique risks due to its ability to generate reactive oxygen species (ROS), leading to oxidative stress and mitochondrial dysfunction.
View Article and Find Full Text PDFIntratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.
JAMA
December 2024
Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand.
Article Synopsis
- Bronchopulmonary dysplasia (BPD) is a serious condition affecting extremely preterm infants, and while systemic corticosteroids can help, they come with risks; inhaled corticosteroids may provide a safer alternative.
- The study aimed to assess the effectiveness of administering budesonide, an inhaled corticosteroid, alongside surfactant in improving survival rates without BPD among extremely preterm infants.
- Conducted across 21 neonatal units in four countries, the trial involved 1,059 infants and found that 25.6% of those receiving budesonide plus surfactant survived without BPD, compared to 22.6% in the surfactant-only group.
EUS-guided transmural drainage of a splenic abscess.
Gastrointest Endosc
November 2024
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
What Psychiatrists Should Know About Prescribed Safer Opioid Supply.
Can J Psychiatry
November 2024
Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
What Psychiatrists Should Know About Prescribed Safer Opioid Supply.
View Article and Find Full Text PDFSafer supply and political interference in medical practice: Alberta's Narcotics Transition Services.
Int J Drug Policy
November 2024
School of Public Health, University of Alberta, Edmonton, Alberta, Canada; Inner City Health and Wellness Program, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
Across much of Canada, opioid poisoning deaths have been increasing due to a toxic, contaminated, and unpredictable drug supply. Multiple prescribed safer supply pilot projects are being implemented and evaluated in an attempt to save lives. In the province of Alberta, however, new regulations introduced in 2022 significantly constrain safer supply prescribing by banning the prescription, dispensing, and administration of safer supply outside of a very limited number of clinics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!